Skip To Content

Study ID: COG ANBL1221


A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

The primary objective of this study is to identify whether temsirolimus or ch14.18 is the optimal therapeutic agent to consider for further testing in a future Phase III randomized trial for treatment of newly diagnosed high-risk neuroblastoma. Participants in this study have been diagnosed with relapsed or refractory neuroblastoma. Neuroblastoma (NBL) develops in nerve cells that are outside of the brain. NBL shows up as a lump or mass in the belly or near the spine in the chest, neck or pelvis. It often spreads to bone, liver, lymph nodes and bone marrow (the soft tissue in the center of bones where blood cells are made).
Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD
NBL (Neuroblastoma)
Phase II
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.